- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Autophagy overview and roles in tumor cell death
Andrew M. Thorburn
Univ. of Colorado Denver, Aurora, CO, United States
- Free
- slides video
- audio + slides
- All slides included
Autophagy in tumor progression to metastasis
Kay F Macleod
Univ. of Chicago Ben May Dept. for Cancer Res., Chicago, IL, United States
- Free
- slides video
- audio + slides
- All slides included
Autophagy in the tumor immune response
Lorenzo Galluzzi
Weill Cornell Medical College, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Targeting autophagy in the clinic and next generation autophagy drugs
Ravi K. Amaravadi
Univ. of Pennsylvania, Philadelphia, PA, United States
- Free
- audio + slides
- Some slides withheld
Next generation humanized mice in cancer research
Leonard D Shultz
The Jackson Laboratory Cancer Ctr., Bar Harbor, ME, United States
- Free
- slides video
- audio + slides
- All slides included
Targeting the innate immune response in models of leukemia and lymphoma
David M Weinstock
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Understanding clonal complexity of human hematologic malignancies by single-cell genomics and PDX modeling
Fumihiko Ishikawa
RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan
- Free
- slides video
- audio + slides
- All slides included
Integrated Genomics for PDX
Carol J Bult
The Jackson Laboratory, Bar Harbor, ME, United States
- Free
- Coming soon
- Some slides withheld
Overview of thyroid cancer: Epidemiology to state-of art standard of care
Steven I. Sherman
UT MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Cancer genomics: Well to poorly differentiated thyroid carcinoma
James A Fagin
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discovering targeted therapies of thyroid cancer using drosophila models
Ross L Cagan
Mount Sinai School of Medicine, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
BRAF-targetedtherapy and mechanisms of resistance in thyroid cancer clinical trials
Manisha H Shah
Ohio State Univ. Comp. Cancer Ctr., Columbus, OH, United States
- Free
- slides video
- audio + slides
- All slides included
Emerging novel RET-Targeted therapy in thyroid cancer
Lori J Wirth
Massachusetts General Hospital, Boston, MA, United States
- Free
- Unknown permission
for presentation
Trial designs for targeted cancer therapies: The case for being inclusive
Tatiana Prowell
U.S. Food and Drug Administration and Johns Hopkins Kimmel Cancer Center, Silver Spring, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Trial designs for targeted cancer therapies:Tackling primary and secondary resistance
Keith Thomas Flaherty
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Incorporation of circulating biomarkers in targeted cancer therapy trials
Lecia V Sequist
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Sequence based DNA methylation analysis
Martin Hirst
The University of British Columbia, Vancouver, BC, Canada
- Free
- slides video
- audio + slides
- All slides included
High-resolution profiling of protein-DNA interaction dynamics
Steven Henikoff
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
- Free
- slides video
- audio + slides
- All slides included
How and why look for clusters of cis-regulatory elements (COREs, aka super-enhancers) in cancer
Mathieu Lupien
Princess Margaret Cancer Ctr., Toronto, ON, Canada
- Permission not
granted for presentation
3D genome organization in cancer
Feng Yue
Penn State University, Hershey, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Using the Cancer Genome Interpreter for gene panel design and variant interpretation
David Tamborero
Univ. of Pompeu Fabra, Barcelona, Spain
- Free
- audio + slides
- Some slides withheld
Using cBioPortal and OncoKB to identify cancer driver alterations and interpret those which are clinically actionable
Debyani Chakravarty
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
MatchMiner: A computational platform for matching patient-specific genomic profiles to precision medicine clinical trials
Catherine A. Del Vecchio Fitz
Dana Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
CIViC: Best practices for curating germline and somatic cancer variants
Obi Lee Griffith
Washington University School of Medicine, Saint Louis, MO, United States
- Permission not
granted for presentation
Angiogenesis revisited: Role and (therapeutic) implications of endothelial metabolism
Peter Carmeliet
VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium